ABBV/ENTA plan to run a Japanese phase-3 trial of ABT-450/r + ABT-267 without ribavirin in GT1b treatment-naïve patients. (Source: ABBV webcast at Morgan Stanley that just finished.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.